ATRC - Company ID 0001323885
AtriCure, Inc. trades as ATRC and has a market capitalization of $1.74 B, making it the #2258 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $534.53M, up 14.9% from the prior year and net income of -$11.45M. This page tracks AtriCure, Inc. through 1,528 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-11
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 9 fiscal years AtriCure, Inc.'s revenue grew from $155.11M to $534.53M, a compound annual growth rate of 14.7%. Net profit margin expanded from -21.5% to -2.1% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Insider trade | 4 | 2026-05-22 |
| Insider trade | 4 | 2026-05-20 |
| Insider sale notice | 144 | 2026-05-20 |
| Insider trade | 4 | 2026-05-20 |
| Insider trade | 4 | 2026-05-20 |
| Insider trade | 4 | 2026-05-20 |
| Insider trade | 4 | 2026-05-20 |
| Insider trade | 4 | 2026-05-20 |
First Quarter 2026 worldwide revenue of $141.2 million , an increase of 14.3% year over year
Fourth Quarter 2025 worldwide revenue of $140.5 million – an increase of 13.1% year over year
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced preliminary financial results for the fourth quarter and full year 2025 and provided 2026 financial guidance.
The largest companies sharing AtriCure, Inc.'s SEC industry classification (surgical & medical instruments & apparatus).
AtriCure, Inc. (ATRC) has a market capitalization of $1.74 B as of 2026-07-11, ranking #2258 among US-listed companies.
AtriCure, Inc. reported revenue of $534.53M for fiscal year 2025, an increase of 14.9% year over year.
In its latest fiscal year AtriCure, Inc. reported a net loss of $11.45M.